A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

RICHMOND, Va., April 30, 2025 (GLOBE NEWSWIRE) -- An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

New research published Tuesday concludes that the rising rate of extreme childhood obesity—well above the usual BMI ...

Secondary outcomes included combined resolution of steatohepatitis and reduction in liver fibrosis, which was reported in 32.7 and 16.1 percent of those in the semaglutide and placebo groups ...

GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD).

VCU-led research highlights semaglutide’s potential for treating fatty liver disease Provided by GlobeNewswire Apr 30, 2025, 10:09:48 PM ...

Semaglutide is not approved to treat MASH in the U.S. Pharmaceutical maker Novo Nordisk has said it plans to seek regulatory approval for its use in treating liver disease sometime this year.